EP1292334A4 - Bispecific fusion protein and method of use for enhancing effector cell killing of target cells - Google Patents
Bispecific fusion protein and method of use for enhancing effector cell killing of target cellsInfo
- Publication number
- EP1292334A4 EP1292334A4 EP01939954A EP01939954A EP1292334A4 EP 1292334 A4 EP1292334 A4 EP 1292334A4 EP 01939954 A EP01939954 A EP 01939954A EP 01939954 A EP01939954 A EP 01939954A EP 1292334 A4 EP1292334 A4 EP 1292334A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fusion protein
- target cells
- effector cell
- cell killing
- bispecific fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000022534 cell killing Effects 0.000 title 1
- 239000012636 effector Substances 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21325200P | 2000-06-22 | 2000-06-22 | |
| US213252P | 2000-06-22 | ||
| PCT/US2001/040835 WO2001097844A1 (en) | 2000-06-22 | 2001-06-04 | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1292334A1 EP1292334A1 (en) | 2003-03-19 |
| EP1292334A4 true EP1292334A4 (en) | 2003-11-19 |
Family
ID=22794334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01939954A Withdrawn EP1292334A4 (en) | 2000-06-22 | 2001-06-04 | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1292334A4 (en) |
| JP (1) | JP2003535908A (en) |
| AU (2) | AU6541801A (en) |
| CA (1) | CA2412901A1 (en) |
| WO (1) | WO2001097844A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106065033A (en) * | 2016-03-17 | 2016-11-02 | 中国药科大学 | The preparation of a kind of cytokine fusion antibody and application thereof |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI290832B (en) | 1999-08-23 | 2007-12-11 | Chugai Pharmaceutical Co Ltd | Expression enhancer for HM1.24 antigen |
| EP1364657B1 (en) | 2001-02-07 | 2016-12-28 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myelocytic leukemia |
| US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
| KR101289537B1 (en) * | 2005-02-15 | 2013-07-31 | 듀크 유니버시티 | Anti-cd19 antibodies and uses in oncology |
| US20070003559A1 (en) * | 2005-07-01 | 2007-01-04 | Wyeth | Methods of determining pharmacokinetics of targeted therapies |
| EP2200634B1 (en) * | 2007-09-21 | 2015-02-11 | The Regents of The University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| JP5699362B2 (en) * | 2008-04-10 | 2015-04-08 | アイビーシー ファーマスーティカルズ,インコーポレイテッド | Modular method for preparing tetrameric cytokines with improved pharmacokinetics by dock-and-lock (DNL) technology |
| WO2011053322A1 (en) * | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| EA034989B1 (en) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Polypeptide construct for use in treating cancer comprising attenuated alpha interferon |
| WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| CA2909952C (en) * | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38 |
| SG11201701867SA (en) | 2014-09-09 | 2017-04-27 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| SG11201703251TA (en) | 2014-10-29 | 2017-05-30 | Teva Pharmaceuticals Australia Pty Ltd | INTERFERON α2B VARIANTS |
| WO2016089960A1 (en) | 2014-12-04 | 2016-06-09 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CA2982452A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| MA42136A (en) | 2015-05-20 | 2018-03-28 | Janssen Biotech Inc | ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS AND OTHER CD38 POSITIVE HEMATOLOGICAL MALIGNANT TUMORS |
| US10668149B2 (en) | 2015-06-22 | 2020-06-02 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| MX2018005315A (en) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER. |
| AU2016343805A1 (en) | 2015-10-30 | 2018-06-07 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PH12018500950B1 (en) | 2015-11-03 | 2023-09-20 | Janssen Biotech Inc | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN109195634A (en) * | 2016-04-15 | 2019-01-11 | 延龄草疗法有限公司 | Macrophage-stimulating in CD47 blocking treatment |
| JP7241677B2 (en) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Anti-CD47 combination therapy |
| WO2019023156A1 (en) * | 2017-07-24 | 2019-01-31 | Rutgers, The State University Of New Jersey | Phosphatidylserine targeting fusion molecules and methods for their use |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| JP6648171B2 (en) * | 2018-02-02 | 2020-02-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Fusion with anti-CD38 antibody and attenuated interferon alpha-2B |
| EP3759144A1 (en) * | 2018-03-01 | 2021-01-06 | Glycotope GmbH | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| CN119264273A (en) | 2019-12-03 | 2025-01-07 | 埃沃特克国际有限责任公司 | Interferon-related antigen binding protein and its use |
| JP6853392B2 (en) * | 2020-01-15 | 2021-03-31 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Fusion with anti-CD38 antibody and attenuated interferon alfa-2B |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0396387A2 (en) * | 1989-05-05 | 1990-11-07 | Research Development Foundation | A novel antibody delivery system for biological response modifiers |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5776456A (en) * | 1992-11-13 | 1998-07-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
-
2001
- 2001-06-04 CA CA002412901A patent/CA2412901A1/en not_active Abandoned
- 2001-06-04 JP JP2002503328A patent/JP2003535908A/en not_active Abandoned
- 2001-06-04 AU AU6541801A patent/AU6541801A/en active Pending
- 2001-06-04 WO PCT/US2001/040835 patent/WO2001097844A1/en not_active Ceased
- 2001-06-04 AU AU2001265418A patent/AU2001265418B2/en not_active Ceased
- 2001-06-04 EP EP01939954A patent/EP1292334A4/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0396387A2 (en) * | 1989-05-05 | 1990-11-07 | Research Development Foundation | A novel antibody delivery system for biological response modifiers |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5776456A (en) * | 1992-11-13 | 1998-07-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5843439A (en) * | 1992-11-13 | 1998-12-01 | Anderson; Darrell R. | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
Non-Patent Citations (4)
| Title |
|---|
| OZZELLO L ET AL: "CONJUGATION OF INTERFERON ALPHA TO A HUMANIZED MONOCLONAL ANTIBODY (HUBRE-3VL) ENHANCES THE SELECTIVE LOCALIZATION AND ANTITUMOR EFFECTS OF INTERFERON IN BREAST CANCER XENOGRAFTS", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 48, no. 2, 1998, pages 135 - 147, XP000940608, ISSN: 0167-6806 * |
| OZZELLO L ET AL: "EXPERIMENTAL IMMUNOTHERAPY OF BREAST CANCER USING ALPHA INTERFERON CONJUGATED TO MONOCLONAL ANTIBODY MC5", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 353, 1994, pages 35 - 46, XP000940596, ISSN: 0065-2598 * |
| PALLELA V R ET AL: "INTERFERON-ALPHA-2B IMMUNOCONJUGATE FOR IMPROVING IMMUNOSCINTIGRAPHY AND IMMUNOTHERAPY", JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE. NEW YORK, US, vol. 41, no. 6, June 2000 (2000-06-01), pages 1108 - 1113, XP000940586, ISSN: 0161-5505 * |
| See also references of WO0197844A1 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106065033A (en) * | 2016-03-17 | 2016-11-02 | 中国药科大学 | The preparation of a kind of cytokine fusion antibody and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003535908A (en) | 2003-12-02 |
| AU2001265418B2 (en) | 2006-03-30 |
| AU6541801A (en) | 2002-01-02 |
| EP1292334A1 (en) | 2003-03-19 |
| WO2001097844A1 (en) | 2001-12-27 |
| CA2412901A1 (en) | 2001-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6541801A (en) | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells | |
| IL153906A0 (en) | Method for direct genetic analysis of target cells | |
| IL208510A0 (en) | Method of collecting placental stem cells | |
| IL207008A (en) | Decellularized or synthetic tissue-s matrices comprising human placental stem cells and methods for preparation thereof | |
| IL149802A0 (en) | Method of cryopreserving selected sperm cells | |
| GB2390221B (en) | Ion beam charge neutralizer and method therefor | |
| AU3064799A (en) | Ion mobility storage trap and method | |
| AU2002360540A1 (en) | Method for intracellular modifications within living cells using pulsed electric fields | |
| AU2003210884A8 (en) | Preparations of nucleus pulposus cells and methods for their generation, identification, and use | |
| AU2786100A (en) | Method of selecting transformed cells and tissues | |
| AU9109001A (en) | Method for use of IGF-binding protein for selective sensitization of target cells in vivo | |
| EP1368029A4 (en) | Method and composition for rejuvinating cells, tissues, organs, hair and nails | |
| AU2002309989A1 (en) | Directed evolution of protein in mammalian cells | |
| AU1417701A (en) | Soluble t cell receptor protein and method of constructing the same | |
| AU8848998A (en) | Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells | |
| AU2002213954A1 (en) | Method for the selective modification of peptides and proteins | |
| AU2003264075A8 (en) | Active fusion proteins and method for the production thereof | |
| AU2003229484A1 (en) | Device and method for cultivating tissue cells | |
| AU2001236064A1 (en) | Method for analysis of substances in tissue or in cells | |
| AU2002333706A1 (en) | Method and means for modulating plant cell cycle proteins and their use in plant cell growth control | |
| HUP0102697A3 (en) | Method of making proteins in transformed yeast cells | |
| HK1069115A (en) | Method for use of igf-binding protein for selective sensitization of target cells in vivo | |
| GB2370039B (en) | Producing protein arrays and fusion protein for use therein | |
| AU2354501A (en) | A new method for the examination of protein localization in living cells | |
| AU1226301A (en) | Stem cell engraftment-enhancing cellular proteins and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20021224 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 39/395 B Ipc: 7C 07K 19/00 A |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20031002 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOGEN IDEC INC. |
|
| 17Q | First examination report despatched |
Effective date: 20050228 |
|
| 17Q | First examination report despatched |
Effective date: 20050228 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOGEN IDEC INC. |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20090723 |